AMP 2023 Annual Meeting & Expo

Transform Oncology with Genomics.

Register for AMP 2023 to attend sessions sponsored by Illumina.

AMP is the primary resource for expertise, education, and collaboration in the field of molecular pathology. AMP members influence policy and regulation on national and international levels, ultimately serving to advance innovation in the field and protect patient access to high-quality appropriate testing.

Join us at Booth #919 to learn how Illumina is transforming oncology with genomics.

____________________________________________________________________________________________________________

Illumina Corporate Workshops

Wednesday, November 15 

Achieving high sensitivity and concordance from CGP from “liquid biopsy” specimens

11:00am – 11:50am MT 
Salt Palace, Room 255A

Comprehensive Genomic Profiling (CGP) of whole blood “liquid biopsy” specimens from cancer patients is being performed in increasing numbers when tumor tissue is inaccessible or unavailable. Consequently, a thorough validation is critical in establishing clinical utility.

In this workshop, we will discuss important considerations when establishing a ctDNA CGP assay to ensure high sensitivity and concordance; share practical implementation challenges and proposed solutions experienced in a community-based, Integrated Network Cancer Program.  We will also highlight the benefits of in-house CGP testing for both tissue and liquid. 

William LaFramboise
Chief Genomics Technology Officer
Allegheny Health Network

Implementing CGP + HRD testing in-house in a large US Healthcare System 

12:00pm – 12:50pm MT 
Salt Palace, Room 255A

Homologous recombination repair deficiency (HRD) is associated with response to poly-ADP-ribose polymerase inhibition (PARPi) therapy in advanced ovarian cancer. In combination with CGP, these analyses allow clinicians to maximize clinical information so that patients are matched with approved therapies or enrolled in relevant clinical trials.  

 In this workshop, a pathologist and laboratory director will discuss the impact of implementing a HRD assay at their institution. They will describe the details of implementing the assay, technical considerations for HRD testing, concordance with other HRD assays, and the added value of offering CGP and HRD testing in-house. 

Carlo Bifulco, MD
Director of Molecular Pathology and Pathology Informatics
Providence St. Joseph Health

Brian Piening, PhD
Associate Member at Earle A. Chiles Research Institute
Technical Director Clinical Genomics at Providence St. Joseph Health

ACMG/AMP/CAP/ClinGen DRAFT Standards for Sequence Variant Classification v4.0

4:00pm – 4:50pm MT
Salt Palace, Room 255D

This session will provide an overview of the draft Standards for Sequence Variant Classification version 4.0, set forth by a joint committee of ACMG, AMP, CAP and ClinGen. The session will include an overview of changes between versions 3.0 and 4.0.

Presenters will speak to reasoning for updates, review draft specifications and supporting materials, and discuss implications for clinical laboratories that classify sequence variants to transition to version 4.0. Attendees will be able to provide feedback and volunteer to test standards. The discussion will include a review of a recent publication assessing rates of variants of uncertain significance in NGS-based testing.

Heidi Rehm, PhD
Chief Genomics Officer, Department of Medicine at Massachusetts General Hospital
Medical Director at The Broad Institute Massachusetts General Hospital

Steven M. Harrison, PhD
Clinical Laboratory Director, Ambry Genetics
Co-chair, ACMG Interpreting Sequence Variants Working Group

____________________________________________________________________________________________________________

Innovation Spotlight Session

Thursday, November 16

Analytical performance of TruSight™ Oncology 500 ctDNA v2:  Improved sensitivity for small nucleotide variants with reduced DNA input requirements and reduced hands-on time

3:45pm – 4:15pm MT
Exhibit Hall, Stage 1

Next-generation sequencing (NGS) based liquid biopsy is emerging as standard of care in oncology for comprehensive genomic profiling (CGP) of solid tumors. In this presentation we will showcase the analytical performance of TruSight™ Oncology 500 ctDNA version 2 (TSO 500 ctDNA v2, Illumina, San Diego, CA; Research Use Only), an NGS-based assay that utilizes the same gene panel as TSO 500 ctDNA. Its improved workflow reduces cfDNA input requirements, total turn-around time and hands-on time while still delivering all key biomarker data available from the TSO 500 gene panel.

Jennifer Lococo
Director, IVD Product Development, IVD Clinical Assay Development
Illumina

Maria Jarama Ruiz
Product Manager, Global Product Management
Illumina

_____________________________________________________________________________________________________________

Exhibit Hours

llumina booth #919

 

Thursday, November 16 
11:15am – 7:00pm MT

Friday, November 17 
9:00am – 4:00pm MT

Saturday, November 18 
9:00am – 1:30pm MT